Fondaparinux: A cornerstone drug in acute coronary syndromes

Table 5 Fondaparinux with unfractionated heparin during revascularization in acute coronary syndromes 8: Secondary outcomes at 30 d

Secondary outcomes at 30 d	Standard dose UFH (n = 1002)	Low dose UFH (n = 1024)	Odds ratio	95%CI	P value
Peri-PCI major bleeding, Death, MI, TVR	3.90%	5.80%	1.51	1.00-2.28	0.05
Death, MI, TVR	2.90%	4.50%	1.58	0.98-2.53	0.06
Death	0.60%	0.80%	1.31	0.45-3.78
MI	2.50%	3.00%	1.22	0.72-2.08
TVR	0.30%	0.90%	2.95	0.80-10.9
Stent thrombosis	0.50%	1.20%	2.36	0.83-6.73	0.11
Catheter thrombosis	0.10%	0.5%	4.91	0.57-42.1	0.15

UFH: Unfractionated heparin; CI: Confidence interval; PCI: Percutaneous coronary intervention; TVR: Target vessel revascularization.